Florham Park, NJNCT07446322Now EnrollingIRB Ready

Ras-mutated Metastatic Colorectal Cancer Clinical Trial in Florham Park, NJ

Access cutting-edge ras-mutated metastatic colorectal cancer treatment through this clinical trial at a research site in Florham Park. Study-provided care at no cost to qualified participants.

Sponsored by Oncolytics Biotech

Quick Self-Assessment

See if you qualify for this Florham Park location

Preparing your pre-screening questions…

Expert Care in Florham Park

Access ras-mutated metastatic colorectal cancer specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ras-mutated metastatic colorectal cancer treatment provided free

Apply for This Florham Park Location

Check if you qualify for this ras-mutated metastatic colorectal cancer clinical trial in Florham Park, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Florham Park

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Florham Park site if eligible
  4. 4Begin participation

About This Ras-mutated Metastatic Colorectal Cancer Study in Florham Park

This is an open-label, randomized, multicenter Phase 2 study to assess the efficacy and safety of FOLFIRI + bevacizumab + pelareorep vs. FOLFIRI + bevacizumab in patients with RAS-mutated, MSS mCRC who have progressed after one prior line of oxaliplatin-based therapy.

Sponsor: Oncolytics Biotech

Who Can Participate

Inclusion Criteria

Histologically confirmed cancer of the colon or rectum with documented metastasis
Measurable disease per RECIST v. 1.1
Not candidates for curative surgery or curative radiation
Progressed on, or been intolerant to, a first-line, oxaliplatin-based chemotherapy regimen in the metastatic setting or relapsed within 6 months of completing adjuvant oxaliplatin
Considered medically eligible to receive standard of care (SOC) FOLFIRI with bevacizumab
Non-microsatellite instability high or non-deficient mismatch repair (non-MSI-H/non dMMR) tumor status per a standard local testing method
Tumor confirmed to harbor a known RAS mutation per a standard local testing method
ECOG performance status of 0 or 1
Patients must have adequate hematological, renal, and hepatic function
Female patients of childbearing potential must have a negative pregnancy test
Life expectancy of at least 6 months

Exclusion Criteria

Undergone systemic chemotherapy, radiotherapy, or surgery, \<4 weeks before study treatment
Ongoing AEs of Grade ≥2 that are related to anti-cancer treatment
Prior treatment with irinotecan
Symptomatic brain metastases
Active autoimmune disease
Receiving immunosuppressive or myelosuppressive medications
Active, uncontrolled infections
Known HIV infection or active hepatitis B or C that requires anti-viral treatment
History of another primary cancer within the last 3 years except for non-melanoma skin cancer, early-stage prostate cancer, or curatively treated cervical carcinoma in-situ
History of allergy or known hypersensitivity to any of the study drugs, study drug classes,
Uncontrolled or severe cardiac disease
Received any vaccine within 28 days prior to first study treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Florham Park?

Yes, this clinical trial (NCT07446322) has an active research site in Florham Park, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ras-mutated Metastatic Colorectal Cancer Treatment Options in Florham Park, NJ

If you're searching for ras-mutated metastatic colorectal cancer treatment options in Florham Park, NJ, this clinical trial (NCT07446322) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Florham Park research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ras-mutated metastatic colorectal cancer specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ras-mutated metastatic colorectal cancer clinical trials near you to find additional studies recruiting in your area.

More Colorectal Cancer Trials in Florham Park, NJ

See all colorectal cancer clinical trials recruiting in Florham Park — not just this study.

Browse Colorectal Cancer Trials in Florham Park →

Browse More Trials by Condition

Colorectal Cancer TrialsEssential Tremor TrialsRheumatoid Arthritis TrialsAnkylosing Spondylitis TrialsErectile Dysfunction TrialsInterstitial Cystitis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Florham Park?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Florham Park, NJ